BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29953740)

  • 1. Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis.
    Ipsen DH; Rolin B; Rakipovski G; Skovsted GF; Madsen A; Kolstrup S; Schou-Pedersen AM; Skat-Rørdam J; Lykkesfeldt J; Tveden-Nyborg P
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):704-713. PubMed ID: 29953740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease.
    Gao H; Zeng Z; Zhang H; Zhou X; Guan L; Deng W; Xu L
    Biol Pharm Bull; 2015; 38(5):694-702. PubMed ID: 25947915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
    Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
    Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model.
    Klaebel JH; Skjødt M; Skat-Rørdam J; Rakipovski G; Ipsen DH; Schou-Pedersen AMV; Lykkesfeldt J; Tveden-Nyborg P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
    Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
    BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerobic exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis.
    Linden MA; Sheldon RD; Meers GM; Ortinau LC; Morris EM; Booth FW; Kanaley JA; Vieira-Potter VJ; Sowers JR; Ibdah JA; Thyfault JP; Laughlin MH; Rector RS
    J Physiol; 2016 Sep; 594(18):5271-84. PubMed ID: 27104887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular drivers of non-alcoholic steatohepatitis are sustained in mild-to-late fibrosis progression in a guinea pig model.
    Ipsen DH; Skat-Rørdam J; Tsamouri MM; Latta M; Lykkesfeldt J; Tveden-Nyborg P
    Mol Genet Genomics; 2019 Jun; 294(3):649-661. PubMed ID: 30759275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon Like Peptide-1 Receptor Agonists Alter Pancreatic and Hepatic Histology and Regulation of Endoplasmic Reticulum Stress in High-fat Diet Mouse Model.
    Fang T; Huang S; Chen Y; Chen Z; Chen J; Hu W
    Exp Clin Endocrinol Diabetes; 2021 Sep; 129(9):625-633. PubMed ID: 32961563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experimental non-alcoholic steatohepatitis in Göttingen Minipigs: consequences of high fat-fructose-cholesterol diet and diabetes.
    Schumacher-Petersen C; Christoffersen BØ; Kirk RK; Ludvigsen TP; Zois NE; Pedersen HD; Vyberg M; Olsen LH
    J Transl Med; 2019 Apr; 17(1):110. PubMed ID: 30943987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
    Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
    Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pomegranate juice prevents development of non-alcoholic fatty liver disease in rats by attenuating oxidative stress and inflammation.
    Noori M; Jafari B; Hekmatdoost A
    J Sci Food Agric; 2017 Jun; 97(8):2327-2332. PubMed ID: 27717115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
    Allam MM; El Gazzar WB
    Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liraglutide protects non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in a mouse model induced by high-fat diet.
    Zhu W; Feng PP; He K; Li SW; Gong JP
    Biochem Biophys Res Commun; 2018 Oct; 505(2):523-529. PubMed ID: 30269815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice.
    Honda T; Ishigami M; Luo F; Lingyun M; Ishizu Y; Kuzuya T; Hayashi K; Nakano I; Ishikawa T; Feng GG; Katano Y; Kohama T; Kitaura Y; Shimomura Y; Goto H; Hirooka Y
    Metabolism; 2017 Apr; 69():177-187. PubMed ID: 28285648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of liraglutide combined with vitamin D on non-alcoholic fatty liver induced by high fat in mice and its mechanism].
    Wang F; Zhang HF
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 May; 36(3):261-264. PubMed ID: 32981283
    [No Abstract]   [Full Text] [Related]  

  • 20. High-fat but not sucrose intake is essential for induction of dyslipidemia and non-alcoholic steatohepatitis in guinea pigs.
    Ipsen DH; Tveden-Nyborg P; Rolin B; Rakipovski G; Beck M; Mortensen LW; Færk L; Heegaard PM; Møller P; Lykkesfeldt J
    Nutr Metab (Lond); 2016; 13():51. PubMed ID: 27512407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.